Dr. Reddy's launches nivolumab biosimilar in India

Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T2NwOSC
via IFTTT

Read More

Centre proposes easier norms for faster drug rollout

India's government plans to streamline drug approval processes for domestic use. Applicants can now start studies after intimating the drug regulator. Import license processing timelines for new drugs will be halved to forty-five days. This move aims to improve the ease of doing business in the sector. However, certain high-risk drug categories will retain existing stringent requirements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cMTsGlP
via IFTTT

Read More

New TB vaccines expected from 2029 could prevent 7.3 million deaths by 2050, Gavi says

By 2029, new tuberculosis vaccines are expected to save more than seven million lives, emerging as a crucial element for global health improvement. Ensuring a steady supply for the countries most affected by the disease is essential. Additionally, these vaccines may provide considerable economic advantages for developing nations. Gavi aims to promote timely accessibility and widespread distribution of these immunizations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y8JHTRa
via IFTTT

Read More

Ayurveda eyes global growth as research, innovation reshape traditional system

Ayurveda is gaining global relevance through research and innovation. Growing interest in holistic healthcare creates new international opportunities for this system. India's Ayush market has seen significant economic growth in recent years. The government promotes Ayush-based medical travel and introduced a dedicated visa. Ayurveda's future international success depends on evidence and standardized practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/irgcVF9
via IFTTT

Read More

Manipal Hospitals scouts for acquisitions in Andhra, Keralam, Delhi-NCR; bets on AI-led healthcare

Manipal Health Enterprises plans significant expansion across several Indian states. The company is adopting a digital-physical healthcare model driven by Artificial Intelligence. Strategic acquisitions and a new greenfield project in Mumbai are underway. Investments focus on AI-enabled nursing and patient monitoring systems. The healthcare major aims to add over 2,400 beds by the year 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ALijwlZ
via IFTTT

Read More

AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mdZjpwy
via IFTTT

Read More

Imported dialysis solution fails endotoxin test in Himachal; lab flags nine regulatory violations

A Himachal Pradesh government drug laboratory has declared two batches of an imported peritoneal dialysis solution “Not of Standard Quality” after they failed bacterial endotoxin tests. The report also flagged nine regulatory violations, including use of non-Indian pharmacopoeial standards, labelling deficiencies, missing safety warnings and inadequate importer details.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fbDLdI7
via IFTTT

Read More